Investigational Anticancer Potential and Targeted Delivery Aspects of Benzyl Isothiocyanate (BITC) in Breast Cancer Treatment.

Breast cancer (BC) remains the most commonly diagnosed cancer among women worldwide and a leading cause of cancer-related mortality. Despite advances in early detection and treatment modalities, challenges such as recurrence, metastasis, and therapy resistance persist, necessitating the development of novel therapeutic strategies. Benzyl isothiocyanate (BITC), a naturally occurring isothiocyanate derived from cruciferous vegetables, has emerged as a promising anticancer agent due to its potent chemopreventive and therapeutic properties. This review comprehensively explores the investigational potential of BITC in the management of breast cancer, emphasizing both its molecular mechanisms and its targeted delivery through nanotechnological approaches. The chemistry and pharmacology of BITC are discussed, highlighting its ability to modulate key signaling pathways, induce apoptosis, inhibit metastasis, and arrest the cell cycle in breast cancer cells. Special attention is given to its pharmacokinetic profile, including bioavailability and metabolic stability, which are crucial for clinical translation. Furthermore, the review examines preclinical findings that demonstrate BITC's suppressive effects on tumor growth and its synergistic interactions with conventional therapies. Innovative strategies for BITC delivery, such as nanoparticle-based systems, are also evaluated for their potential to enhance therapeutic efficacy and reduce systemic toxicity. The safety profile and toxicity considerations of BITC are critically assessed based on current preclinical evidence. By synthesizing findings from a broad range of preclinical studies, this review underscores the multifaceted anticancer potential of BITC and its promise as a complementary or alternative approach in breast cancer treatment. Continued research into its mechanistic actions, delivery optimization, and translational applications is essential to harness BITC's full potential in improving patient outcomes.